SCHEMBL1930732

SCHEMBL1930732

NCc1ccc(-n2cc(CO)cn2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.43
GABRR1 P24046 1/20 0.43
GABRA3 P34903 1/20 0.43
GABRA2 P47869 1/20 0.43
GABRB2 P47870 1/20 0.43
DRD4 P21917 7/20 0.38
HTR2C P28335 2/20 0.38
DRD2 P14416 5/20 0.38
DRD3 P35462 4/20 0.38
GAA P10253 2/20 0.37
LMNA P02545 3/20 0.37
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
NR4A1 P22736 1/20 0.37
MPI P34949 1/20 0.37
RECQL P46063 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6530604 0.83 LMNA (0.41) DRD4HTR2CDRD2DRD3GAA
SCHEMBL27706821 0.83 GABRA1 (0.39) GABRA1GABRR1GABRA3GABRA2GABRB2
SCHEMBL28980400 0.81 MEN1 (0.41) DRD4HTR2CDRD2DRD3GAA
SCHEMBL6533912 0.81 DRD4 (0.55) DRD4HTR2CDRD2DRD3LMNA
SCHEMBL6533713 0.81 NOTUM (0.51) DRD4HTR2CDRD2DRD3GAA
SCHEMBL15180418 0.81 DRD4 (0.52) DRD4HTR2CDRD2DRD3GAA
SCHEMBL27903903 0.81 PARP1 (0.40) GABRA1GABRR1GABRA3GABRA2GABRB2
SCHEMBL2412911 0.80 GAA (0.58) DRD4HTR2CDRD2DRD3GAA
SCHEMBL1312810 0.79 DRD4 (0.44) DRD4HTR2CDRD2DRD3GAA
SCHEMBL12853643 0.79 GABRA1 (0.36) GABRA1GABRR1GABRA3GABRA2GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2312949-B1 N-HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME (US) 2013-08-28 EP disclosed
EP-2312949-B1 N-HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME (US) 2013-08-28 EP disclosed
US-8426598-B2 N-heterocyclic M1 receptor positive allosteric modulators Merck, Sharp & Dohme, Corp. (US) 2013-04-23 US disclosed
US-8426598-B2 N-heterocyclic M1 receptor positive allosteric modulators Merck, Sharp & Dohme, Corp. (US) 2013-04-23 US disclosed
US-8426598-B2 N-heterocyclic M1 receptor positive allosteric modulators Merck, Sharp & Dohme, Corp. (US) 2013-04-23 US disclosed
US-20110136863-A1 N-Heterocyclic M1 Receptor Positive Allosteric Modulators MERCK SHARP & DOHME LLC 2011-06-09 US disclosed
US-20110136863-A1 N-Heterocyclic M1 Receptor Positive Allosteric Modulators MERCK SHARP & DOHME LLC 2011-06-09 US disclosed
US-20110136863-A1 N-Heterocyclic M1 Receptor Positive Allosteric Modulators MERCK SHARP & DOHME LLC 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136863-A1 N-Heterocyclic M1 Receptor Positive Allosteric Modulators CHRM1, OPRL1, OPRM1 GABRA1 204/4885GABRR1 262/4885GABRA3 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.